Failed TIL…Jim B and others need advice.

Look for trials that use CT 011

http://www.curetechbio.com/?TemplateID=29&PageID=145&TemplateType=14

CT-011 is a humanized monoclonal antibody (mAb) that modulates the immune response and inhibits tumor growth and the spread of metastases. CT-011 interacts with PD-1 (Programmed Death-1), an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells. Mechanistically, CT-011 blocks the function of PD-1, resulting in the attenuation of apoptotic processed in lymphocytes, primarily effector/memory T cells. CT-011 also augments anti-tumor activities of NK cells. The enhanced activities of T and NK cells are translated into the intensification of anti-tumor immune response and the generation of tumor-specific memory cells. CT-011 is being developed as a treatment for hematological malignancies and solid tumors.

PD-1 and its ligand, PD-L1, have been demonstrated to play a central role in tumor recurrence and progression . The presence of these molecules on different tumors including different kinds of lymphoma, colorectal carcinoma, renal cell carcinoma and others, has been associated with poor prognosis and their expression was correlated with immune suppression at tumor-involved sites. In a workshop held by the National Cancer Institute in 2007, anti PD-1 agents were placed second in-rank out of 124 agents, for their potential to provide efficient immunotherapy for cancer.

The efficacy of CT-011 was studied in a variety of experimental tumor models for leukemia/lymphoma, melanoma, lung, colon, fibrosarcoma, breast cancer and more. In all these models, single or multiple antibody doses administered 10–14 days post tumor inoculation were able to inhibit tumor growth, to extend the survival of tumor-bearing mice, and to generate tumor-specific protection against tumor re-challenge.

A Phase I, dose escalation, clinical study in 17 hematological malignancy patients has been completed. The study showed that a single administration of CT-011 (0.2 to 6.0mg/kg) was overall safe and well tolerated with no observed serious/unexpected treatment-related adverse events and no observed infusion-related responses or autoimmune reactions. No single dose MTD could be established in this study. Interestingly, apparent clinical responses were observed in six of the patients exhibited as extended survival as follows: one Complete Remission (NHL – follicular lymphoma), four Stable Disease (HD, 2 CLL, and MM), and one minimal response (AML). Amongst immune modulating molecules, CT-011 presents a safe alternative exhibiting no signs of autoimmunity which commonly occurs in the presence of other immune-modulating antibodies.

A Phase II safety and efficacy study of CT-011 in patients with diffuse large B-cell lymphoma following autologous stem cell transplantation is underway in the US and Israel. Another clinical study will evaluate the safety and preliminary efficacy of CT-011 in patients suffering from a variety of metastatic cancer diseases will be initiated in the second half of 2008.

How does CT-011 work? Watch The Movie >

Look for trials that use CT 011

http://www.curetechbio.com/?TemplateID=29&PageID=145&TemplateType=14

CT-011 is a humanized monoclonal antibody (mAb) that modulates the immune response and inhibits tumor growth and the spread of metastases. CT-011 interacts with PD-1 (Programmed Death-1), an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells. Mechanistically, CT-011 blocks the function of PD-1, resulting in the attenuation of apoptotic processed in lymphocytes, primarily effector/memory T cells. CT-011 also augments anti-tumor activities of NK cells. The enhanced activities of T and NK cells are translated into the intensification of anti-tumor immune response and the generation of tumor-specific memory cells. CT-011 is being developed as a treatment for hematological malignancies and solid tumors.

PD-1 and its ligand, PD-L1, have been demonstrated to play a central role in tumor recurrence and progression . The presence of these molecules on different tumors including different kinds of lymphoma, colorectal carcinoma, renal cell carcinoma and others, has been associated with poor prognosis and their expression was correlated with immune suppression at tumor-involved sites. In a workshop held by the National Cancer Institute in 2007, anti PD-1 agents were placed second in-rank out of 124 agents, for their potential to provide efficient immunotherapy for cancer.

The efficacy of CT-011 was studied in a variety of experimental tumor models for leukemia/lymphoma, melanoma, lung, colon, fibrosarcoma, breast cancer and more. In all these models, single or multiple antibody doses administered 10–14 days post tumor inoculation were able to inhibit tumor growth, to extend the survival of tumor-bearing mice, and to generate tumor-specific protection against tumor re-challenge.

A Phase I, dose escalation, clinical study in 17 hematological malignancy patients has been completed. The study showed that a single administration of CT-011 (0.2 to 6.0mg/kg) was overall safe and well tolerated with no observed serious/unexpected treatment-related adverse events and no observed infusion-related responses or autoimmune reactions. No single dose MTD could be established in this study. Interestingly, apparent clinical responses were observed in six of the patients exhibited as extended survival as follows: one Complete Remission (NHL – follicular lymphoma), four Stable Disease (HD, 2 CLL, and MM), and one minimal response (AML). Amongst immune modulating molecules, CT-011 presents a safe alternative exhibiting no signs of autoimmunity which commonly occurs in the presence of other immune-modulating antibodies.

A Phase II safety and efficacy study of CT-011 in patients with diffuse large B-cell lymphoma following autologous stem cell transplantation is underway in the US and Israel. Another clinical study will evaluate the safety and preliminary efficacy of CT-011 in patients suffering from a variety of metastatic cancer diseases will be initiated in the second half of 2008.

How does CT-011 work? Watch The Movie >

Look for trials that use CT 011

http://www.curetechbio.com/?TemplateID=29&PageID=145&TemplateType=14

CT-011 is a humanized monoclonal antibody (mAb) that modulates the immune response and inhibits tumor growth and the spread of metastases. CT-011 interacts with PD-1 (Programmed Death-1), an inhibitory receptor belonging to the B7-receptor family that is expressed on lymphocytes and myeloid cells. Mechanistically, CT-011 blocks the function of PD-1, resulting in the attenuation of apoptotic processed in lymphocytes, primarily effector/memory T cells. CT-011 also augments anti-tumor activities of NK cells. The enhanced activities of T and NK cells are translated into the intensification of anti-tumor immune response and the generation of tumor-specific memory cells. CT-011 is being developed as a treatment for hematological malignancies and solid tumors.

PD-1 and its ligand, PD-L1, have been demonstrated to play a central role in tumor recurrence and progression . The presence of these molecules on different tumors including different kinds of lymphoma, colorectal carcinoma, renal cell carcinoma and others, has been associated with poor prognosis and their expression was correlated with immune suppression at tumor-involved sites. In a workshop held by the National Cancer Institute in 2007, anti PD-1 agents were placed second in-rank out of 124 agents, for their potential to provide efficient immunotherapy for cancer.

The efficacy of CT-011 was studied in a variety of experimental tumor models for leukemia/lymphoma, melanoma, lung, colon, fibrosarcoma, breast cancer and more. In all these models, single or multiple antibody doses administered 10–14 days post tumor inoculation were able to inhibit tumor growth, to extend the survival of tumor-bearing mice, and to generate tumor-specific protection against tumor re-challenge.

A Phase I, dose escalation, clinical study in 17 hematological malignancy patients has been completed. The study showed that a single administration of CT-011 (0.2 to 6.0mg/kg) was overall safe and well tolerated with no observed serious/unexpected treatment-related adverse events and no observed infusion-related responses or autoimmune reactions. No single dose MTD could be established in this study. Interestingly, apparent clinical responses were observed in six of the patients exhibited as extended survival as follows: one Complete Remission (NHL – follicular lymphoma), four Stable Disease (HD, 2 CLL, and MM), and one minimal response (AML). Amongst immune modulating molecules, CT-011 presents a safe alternative exhibiting no signs of autoimmunity which commonly occurs in the presence of other immune-modulating antibodies.

A Phase II safety and efficacy study of CT-011 in patients with diffuse large B-cell lymphoma following autologous stem cell transplantation is underway in the US and Israel. Another clinical study will evaluate the safety and preliminary efficacy of CT-011 in patients suffering from a variety of metastatic cancer diseases will be initiated in the second half of 2008.

How does CT-011 work? Watch The Movie >

Hi Val,

How were your scans?

If you do not have any internal lesions & it is only surface based based melanoma, maybe you should be looking for a different kind of treatment to treat surface melanoma.

How are you feeling? Are you able to eat & keep the food down?

My prayers go out to you.

Mary

Hi Val,

How were your scans?

If you do not have any internal lesions & it is only surface based based melanoma, maybe you should be looking for a different kind of treatment to treat surface melanoma.

How are you feeling? Are you able to eat & keep the food down?

My prayers go out to you.

Mary

Hi Val,

How were your scans?

If you do not have any internal lesions & it is only surface based based melanoma, maybe you should be looking for a different kind of treatment to treat surface melanoma.

How are you feeling? Are you able to eat & keep the food down?

My prayers go out to you.

Mary

Val,  I had the exact same thing happen to me a year ago.  I had my TIL treatment in November 2010, with IL2  and chemo.  For one straight year previous to this I went to NIH from California, a long flight, to qualify to get this treatment.  I was so hopeful.  Then in December, they put my in a room and told me it didn't work.  I cried.  A Doctor since told me it was probably because I had biochemo, and people that have had biochemo usually fail TIL.  I wish they had told me that.  I hope my experience helps someone else.  NIH is a great hospital.  I spent Thanksgiving there last year. 

failed interferon, biochemo, and TIL.   On yervoy at this( 2nd) time.

Good luck, Val. 
 

Val,  I had the exact same thing happen to me a year ago.  I had my TIL treatment in November 2010, with IL2  and chemo.  For one straight year previous to this I went to NIH from California, a long flight, to qualify to get this treatment.  I was so hopeful.  Then in December, they put my in a room and told me it didn't work.  I cried.  A Doctor since told me it was probably because I had biochemo, and people that have had biochemo usually fail TIL.  I wish they had told me that.  I hope my experience helps someone else.  NIH is a great hospital.  I spent Thanksgiving there last year. 

failed interferon, biochemo, and TIL.   On yervoy at this( 2nd) time.

Good luck, Val. 
 

Val,  I had the exact same thing happen to me a year ago.  I had my TIL treatment in November 2010, with IL2  and chemo.  For one straight year previous to this I went to NIH from California, a long flight, to qualify to get this treatment.  I was so hopeful.  Then in December, they put my in a room and told me it didn't work.  I cried.  A Doctor since told me it was probably because I had biochemo, and people that have had biochemo usually fail TIL.  I wish they had told me that.  I hope my experience helps someone else.  NIH is a great hospital.  I spent Thanksgiving there last year. 

failed interferon, biochemo, and TIL.   On yervoy at this( 2nd) time.

Good luck, Val. 
 

Val, I am sorry to read that TIL has been ineffective for you. I have just had a quick
read of your profile, and I now wonder if you have primary dermal melanoma? See:
http://www.ncbi.nlm.nih.gov/pubmed/18209168

If this is the case, then perhaps a different approach such as PV-10 would be worth
considering?

Here is some info on a PV-10 (Rose Bengal) trial:
http://www.clinicaltrials.gov/ct2/show/NCT01260779?term=PV-10+melanoma&rank=3

This is an old video about it:
http://www.youtube.com/watch?v=HSjoev_q9Nw

The company's website is at:
http://www.pvct.com/

Hope this helps.

Frank from Australia

Val, I am sorry to read that TIL has been ineffective for you. I have just had a quick
read of your profile, and I now wonder if you have primary dermal melanoma? See:
http://www.ncbi.nlm.nih.gov/pubmed/18209168

If this is the case, then perhaps a different approach such as PV-10 would be worth
considering?

Here is some info on a PV-10 (Rose Bengal) trial:
http://www.clinicaltrials.gov/ct2/show/NCT01260779?term=PV-10+melanoma&rank=3

This is an old video about it:
http://www.youtube.com/watch?v=HSjoev_q9Nw

The company's website is at:
http://www.pvct.com/

Hope this helps.

Frank from Australia

Val, I am sorry to read that TIL has been ineffective for you. I have just had a quick
read of your profile, and I now wonder if you have primary dermal melanoma? See:
http://www.ncbi.nlm.nih.gov/pubmed/18209168

If this is the case, then perhaps a different approach such as PV-10 would be worth
considering?

Here is some info on a PV-10 (Rose Bengal) trial:
http://www.clinicaltrials.gov/ct2/show/NCT01260779?term=PV-10+melanoma&rank=3

This is an old video about it:
http://www.youtube.com/watch?v=HSjoev_q9Nw

The company's website is at:
http://www.pvct.com/

Hope this helps.

Frank from Australia

Val, would any of the info about cremes that I posted in response to Shimian;s post =11/4/2011-2:40pm

(http://www.melanoma.org/community/mpip-melanoma-patients-information-page/keep-getting-postive-margin-after-3-wide-excisions)

at  

Val, would any of the info about cremes that I posted in response to Shimian;s post =11/4/2011-2:40pm

(http://www.melanoma.org/community/mpip-melanoma-patients-information-page/keep-getting-postive-margin-after-3-wide-excisions)

at  

Val, would any of the info about cremes that I posted in response to Shimian;s post =11/4/2011-2:40pm

(http://www.melanoma.org/community/mpip-melanoma-patients-information-page/keep-getting-postive-margin-after-3-wide-excisions)

at  

You did not fail anything.  You chose or were directed to a treatment that did not work.

YOU did not fail anything.

I realize to some this may seem a matter of semantics and petty, but after more than a half dozen recurrences. I can assure you, that  to mention "you failed" is not a term that does anything to enhance cancer diagnosis or treatment coping skills.

Failure, to me, as far as cancer is concerned, is defined as not accepting responsibility for the existing problem and refusing to act.

Yes, it is a mindset and no, mindset alone is not always enough to kick melanoma to the curb.

But to associate a treatment that did not work with failure is wrong headed and sets the mind in a rear view approach that serves no useful purpose other than a matter of exclusion;  as opposed to a mindset of forward thinking.

 Use it as a tool that allows you to direct your care,  to free you and force others around you  to not only work the problem but find solutions.

It gets my hackles up (whatever hackles are) when patients mention failure..  A treatment did not work, the issue therefor is not one of failure, but a springboard towards the   search for success.

Try that attitude with your doctors , let it be known you are the Captain of the Ship and challenge them, as your crew to guide you through this storm.

That mindset will take you far inn dealing with and coping with melanoma.

It's about the only control one has in a seemingly uncontrollable situation.

Just a thought.

Cheers,

Charlie S

You did not fail anything.  You chose or were directed to a treatment that did not work.

YOU did not fail anything.

I realize to some this may seem a matter of semantics and petty, but after more than a half dozen recurrences. I can assure you, that  to mention "you failed" is not a term that does anything to enhance cancer diagnosis or treatment coping skills.

Failure, to me, as far as cancer is concerned, is defined as not accepting responsibility for the existing problem and refusing to act.

Yes, it is a mindset and no, mindset alone is not always enough to kick melanoma to the curb.

But to associate a treatment that did not work with failure is wrong headed and sets the mind in a rear view approach that serves no useful purpose other than a matter of exclusion;  as opposed to a mindset of forward thinking.

 Use it as a tool that allows you to direct your care,  to free you and force others around you  to not only work the problem but find solutions.

It gets my hackles up (whatever hackles are) when patients mention failure..  A treatment did not work, the issue therefor is not one of failure, but a springboard towards the   search for success.

Try that attitude with your doctors , let it be known you are the Captain of the Ship and challenge them, as your crew to guide you through this storm.

That mindset will take you far inn dealing with and coping with melanoma.

It's about the only control one has in a seemingly uncontrollable situation.

Just a thought.

Cheers,

Charlie S

You did not fail anything.  You chose or were directed to a treatment that did not work.

YOU did not fail anything.

I realize to some this may seem a matter of semantics and petty, but after more than a half dozen recurrences. I can assure you, that  to mention "you failed" is not a term that does anything to enhance cancer diagnosis or treatment coping skills.

Failure, to me, as far as cancer is concerned, is defined as not accepting responsibility for the existing problem and refusing to act.

Yes, it is a mindset and no, mindset alone is not always enough to kick melanoma to the curb.

But to associate a treatment that did not work with failure is wrong headed and sets the mind in a rear view approach that serves no useful purpose other than a matter of exclusion;  as opposed to a mindset of forward thinking.

 Use it as a tool that allows you to direct your care,  to free you and force others around you  to not only work the problem but find solutions.

It gets my hackles up (whatever hackles are) when patients mention failure..  A treatment did not work, the issue therefor is not one of failure, but a springboard towards the   search for success.

Try that attitude with your doctors , let it be known you are the Captain of the Ship and challenge them, as your crew to guide you through this storm.

That mindset will take you far inn dealing with and coping with melanoma.

It's about the only control one has in a seemingly uncontrollable situation.

Just a thought.

Cheers,

Charlie S

Val,

plan a visit to Jeff Weber at Moffitt in Tampa, Fl…he is very accessible,smart and helpful and has certainly helped me and others on this site…i feel he would know what to do and he would talk and coordinate with your onc if you go and see him…he also has some very effective drug trials going and can tell you if you qualify or not…

boots

Val,

plan a visit to Jeff Weber at Moffitt in Tampa, Fl…he is very accessible,smart and helpful and has certainly helped me and others on this site…i feel he would know what to do and he would talk and coordinate with your onc if you go and see him…he also has some very effective drug trials going and can tell you if you qualify or not…

boots

Val,

plan a visit to Jeff Weber at Moffitt in Tampa, Fl…he is very accessible,smart and helpful and has certainly helped me and others on this site…i feel he would know what to do and he would talk and coordinate with your onc if you go and see him…he also has some very effective drug trials going and can tell you if you qualify or not…

boots